Stock Events

Stock Events

AN2 Therapeutics 

$4.65
7
+$0.12+2.65% 13:24 Today

Statistics

Day High
4.55
Day Low
4.53
52W High
6.28
52W Low
1.03
Volume
12,339
Avg. Volume
-
Mkt Cap
170.95M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
May 2018
$0.66
Feb 2018
$0.66
Nov 2017
$0.66
Aug 2017
$0.66
May 2017
$0.66
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

Nov 5Expected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.35
-0.29
-0.24
-0.18
Expected EPS
-0.2
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
2025
0Revenue
-35.17MNet Income

Analyst Ratings

$9.00Average Price Target
The highest estimate is ⁦9.00⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ANTX. It's not an investment recommendation.
Tesla
2
TSLA
NVIDIA
2
NVDA
Verizon Communications
2
VZ
Strategy
2
MSTR

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals is involved in developing treatments for cystic fibrosis and other diseases, competing in the biotech space with AN2 Therapeutics' focus on infectious diseases.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, directly competing with AN2's infectious disease portfolio.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie operates in the same biopharmaceutical field, developing drugs for conditions like rheumatoid arthritis and Crohn's disease, which could overlap with AN2 Therapeutics' market.
Merck
MRK
Mkt Cap368.89B
Merck & Co. is a global healthcare company that produces medicines, vaccines, biologic therapies, and animal health products, competing in the infectious disease market.
Pfizer
PFE
Mkt Cap173.95B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology and infectious diseases, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for various diseases, potentially competing with AN2 Therapeutics in the healthcare market.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca operates in several therapeutic areas, including respiratory, cardiovascular, and infectious diseases, directly competing with AN2 Therapeutics.
Novartis
NVS
Mkt Cap303.67B
Novartis focuses on a broad range of healthcare areas, including the development of treatments for infectious diseases, making it a competitor.
AMGEN
AMGN
Mkt Cap251.94B
Amgen focuses on human therapeutics, including treatments for infectious diseases, which could compete with AN2 Therapeutics' product pipeline.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb is a global biopharmaceutical company focusing on discovering, developing, and delivering innovative medicines, including for infectious diseases, competing with AN2 Therapeutics.

About

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
Show More
CEO
Eric E. Easom
Employees
21
Country
United States
ISIN
US0373261058

Listings

XNAS
US
ANTX
BOATS
BOATS
ANTX.BOATS

0 Comments

Share your thoughts

FAQs

What is AN2 Therapeutics stock price today?▼
The current price of ANTX is $4.65 USD — it has increased by +2.65% in the past 24 hours. Watch AN2 Therapeutics stock price performance more closely on the chart.
What is AN2 Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange AN2 Therapeutics stocks are traded under the ticker ANTX.
Is AN2 Therapeutics stock price growing?▼
ANTX stock has risen by +24.79% compared to the previous week, the month change is a -20.67% fall, over the last year AN2 Therapeutics has showed a +268.29% increase.
What is AN2 Therapeutics market cap?▼
Today AN2 Therapeutics has the market capitalization of 170.95M
When is the next AN2 Therapeutics earnings date?▼
AN2 Therapeutics is going to release the next earnings report on November 5, 2026.
What were AN2 Therapeutics earnings last quarter?▼
ANTX earnings for the last quarter are -0.18 USD per share, whereas the estimation was -0.24 USD resulting in a +25% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is AN2 Therapeutics revenue for the last year?▼
AN2 Therapeutics revenue for the last year amounts to 0 USD.
What is AN2 Therapeutics net income for the last year?▼
ANTX net income for the last year is -35.17M USD.
Does AN2 Therapeutics pay dividends?▼
Yes, ANTX dividends are paid quarterly. The last dividend per share was 0.66 . As of today, Dividend Yield (FWD)% is 0%.
How many employees does AN2 Therapeutics have?▼
As of November 2, 2026, the company has 21 employees.
In which sector is AN2 Therapeutics located?▼
AN2 Therapeutics operates in the Health & Wellness sector.
When did AN2 Therapeutics complete a stock split?▼
AN2 Therapeutics has not had any recent stock splits.
Where is AN2 Therapeutics headquartered?▼
AN2 Therapeutics is headquartered in MENLO PARK, United States.